Misoprostol (DB00929): A Comprehensive Pharmacological and Clinical Monograph

Executive Summary

Misoprostol is a synthetic prostaglandin E1 (PGE1) analogue, a small molecule drug with a remarkable and complex dual identity in modern medicine.[1] Originally developed and granted FDA approval in 1988 for a narrow indication—the prevention of gastric ulcers induced by nonsteroidal anti-inflammatory drugs (NSAIDs)—its clinical profile has been profoundly reshaped by its extensive and potent off-label applications in obstetrics and gynecology.[3] This report provides an exhaustive analysis of misoprostol, synthesizing its chemical properties, pharmacological mechanisms, multifaceted clinical uses, and critical safety considerations.

The drug's primary mechanism for its approved indication involves acting as a prostaglandin agonist on gastric parietal cells, where it inhibits acid secretion and provides a cytoprotective effect by enhancing the secretion of mucus and bicarbonate.[3] This directly counteracts the mucosal damage caused by NSAIDs. Concurrently, misoprostol exerts powerful uterotonic effects by binding to prostaglandin receptors in the myometrium and cervix, leading to increased uterine contractility and cervical ripening.[1] This second mechanism forms the basis for its widespread off-label use in labor induction, medical termination of pregnancy, management of miscarriage, and prevention and treatment of postpartum hemorrhage.[3]

A defining feature of misoprostol is the critical influence of the administration route on its pharmacokinetic profile. Oral and sublingual routes provide rapid peak plasma concentrations ideal for acute interventions, whereas vaginal and rectal administration result in slower absorption and sustained action, suitable for applications like labor induction.[3] This deliberate manipulation of pharmacokinetics is a cornerstone of its versatile clinical application.

The safety profile of misoprostol is dominated by a U.S. Food and Drug Administration (FDA) Black Box Warning. This warning highlights the severe risks of its use in pregnant women for its ulcer-prevention indication, including the potential for abortion, premature birth, birth defects, and life-threatening uterine rupture.[8] This paradox—where the drug's therapeutic effect in one domain constitutes its greatest risk in another—necessitates stringent patient selection, counseling, and a deep understanding of its properties for safe use. This monograph serves as a definitive reference, elucidating the science and clinical practice surrounding this uniquely multifaceted therapeutic agent.

Chemical Identity and Physicochemical Properties

A comprehensive understanding of misoprostol's clinical pharmacology begins with a precise characterization of its chemical and physical nature. As a synthetic small molecule, its structure, stability, and formulation are fundamental to its biological activity and delivery.

Nomenclature and Identification

Misoprostol is recognized by a variety of names and unique identifiers across chemical, regulatory, and commercial domains. This standardized nomenclature is essential for accurate communication and research.

• Generic Name: Misoprostol. The Latin form, Misoprostolum, is also used in some pharmacopeias.[3]
• Brand Names: The most widely known brand name is Cytotec. It is also a component of combination products, such as Arthrotec (combined with the NSAID diclofenac) and Mifegymiso (combined with mifepristone for medical abortion). Other brand names include Misodel and Misopess.[3]
• Systematic (IUPAC) Name: The formal IUPAC name is methyl 7--5-oxocyclopentyl]heptanoate.[10] Other systematic names, such as (11α,13E)-(±)-11,16-Dihydroxy-16-methyl-9-oxoprost-13-en-1-oic acid methyl ester, are also used.[9]
• Synonyms: The compound is referenced by numerous synonyms in research and commercial literature, including SC-29333, Misogon, and Misoprostil.[12]
• Key Identification Codes:
• DrugBank ID: DB00929 [3]
• CAS Number: 59122-46-2 [11]
• FDA UNII (Unique Ingredient Identifier): 0E43V0BB57 [10]
• ATC Codes: A02BB01 (Drugs for peptic ulcer and GORD, Prostaglandins), G02AD06 (Other gynecologicals, Prostaglandins) [13]
• Transport and Trade Codes: UN Number: UN2810; Harmonized System (HS) Code: 293750 [15]

Chemical and Molecular Data

Misoprostol's molecular structure is the basis for its function as a prostaglandin analogue and prodrug.

• Drug Type: Small Molecule.[3]
• Chemical Formula: C22​H38​O5​.[3]
• Molecular Weight: The average molecular weight is consistently reported as 382.53-382.54 g/mol, with a precise monoisotopic mass of 382.271924326 Da.[3]
• Stereochemistry: The commercially available drug is a racemic mixture containing approximately equal amounts of two diastereomers. The stereoisomer (11R,16S)-misoprostol (CAS 59122-49-5) has been identified as a pharmacologically active component, responsible for its anti-ulcer and abortifacient properties.[17] The presence of multiple stereocenters and a trans double bond ( 13E) are defining structural features.[9]
• Structure Identifiers:
• SMILES: CCCCC(C)(O)C/C=C/[C@H]1C(O)CC(=O)C1CCCCCCC(=O)OC [11]
• InChIKey: OJLOPKGSLYJEMD-URPKTTJQSA-N [10]

The structure itself reveals a critical aspect of its pharmacology. The methyl ester group (-C(=O)OC) at one end of the molecule is not present in naturally occurring prostaglandins. This modification makes misoprostol a prodrug. It is biologically inert in its initial form and requires metabolic conversion—specifically, the cleavage of this ester group (de-esterification)—to form its active metabolite, misoprostol acid.[1] This chemical design feature is crucial for its pharmacokinetic profile, particularly its absorption and stability after oral administration.

Physicochemical and Formulation Properties

The physical state and solubility of misoprostol dictate its formulation into a stable and effective dosage form.

• Appearance: In its pure form, misoprostol is described as a viscous liquid, often appearing as a pale yellow oil or a colorless gel.[14]
• Solubility: It is practically insoluble in water but soluble in organic solvents such as ethanol (96%) and sparingly soluble in acetonitrile.[13] It is also highly soluble in dimethylformamide (DMF) and dimethyl sulfoxide (DMSO).[12]
• Formulation: To create a solid dosage form from a viscous liquid, misoprostol is formulated into tablets. Standard oral tablets are available in strengths of 100 micrograms (mcg) and 200 mcg.[18] A 25 mcg tablet is also available for specific obstetric applications.[21] These tablets contain several inactive ingredients (excipients) to ensure stability, form, and proper dissolution, including microcrystalline cellulose, hydrogenated castor oil, and sodium starch glycolate.[16]
• Stability and Storage: Storage conditions vary by product grade. Pharmaceutical-grade tablets are typically stored at or below 30°C in their original packaging to protect from moisture.[22] Research-grade material, due to its purity and intended use in sensitive assays, may require more stringent conditions, such as storage at -20°C under desiccating conditions and shipment on blue ice.[11]
• Transport Classification: Reflecting its potent biological activity and potential for harm or misuse if handled improperly, misoprostol is classified as a Dangerous Good for transport (UN No: UN2810), which may require special shipping methods and charges.[15] This classification is a direct consequence of its powerful abortifacient properties, linking its chemical identity to its significant societal and regulatory context.

The table below consolidates the key chemical and physical properties of misoprostol.

Table 1: Physicochemical Properties of Misoprostol

Property	Value	Source(s)
Generic Name	Misoprostol	3
DrugBank ID	DB00929	3
CAS Number	59122-46-2	11
Chemical Formula	C22​H38​O5​	3
Average Molecular Weight	382.54 g/mol	3
IUPAC Name	methyl 7--5-oxocyclopentyl]heptanoate	10
Appearance	Pale yellow oil; viscous liquid; colorless gel	14
Solubility (Water)	Practically insoluble	13
Solubility (Other)	Soluble in ethanol; sparingly soluble in acetonitrile	13
Standard Formulation	100 mcg or 200 mcg oral tablets	18
Storage Conditions	Store at or below 30°C; protect from moisture	22

Pharmacology and Mechanism of Action

Misoprostol's diverse clinical effects stem from its function as a synthetic prostaglandin E1 (PGE1) analogue that interacts with multiple prostanoid receptor subtypes.[1] Its mechanism of action is distinctly tissue-dependent, leading to two primary, and seemingly disparate, pharmacological outcomes: gastroprotection and uterine stimulation. The specific clinical effect observed is determined not by the drug itself, but by the unique expression profile of prostaglandin receptors in the target organ.

Receptor Binding Profile

Misoprostol is not a highly selective agent. It functions as a broad agonist, primarily targeting several subtypes of the prostaglandin E2 (PGE2) receptor: EP1, EP2, EP3, and EP4.[3] While it is a PGE1 analogue, it exerts its effects through these PGE2 receptors. The affinity of misoprostol for these receptors varies, which contributes to its complex pharmacological profile.

Published binding affinity data show some variability, likely due to different experimental conditions, but consistently point to potent activity at the EP3 receptor. One study reports inhibition constants (Ki​) of 250 nM for the EP2 receptor and 67 nM for both EP3 and EP4 receptors.[11] Another, more detailed analysis using recombinant human receptors found

Ki​ values of 35.675 µM for EP1, 10.249 µM for EP2, 5.499 µM for EP4, and a particularly high affinity for the EP3-III isoform with a Ki​ of 0.319 µM (319 nM).[12] In contrast, its affinity for other prostanoid receptors, such as DP, FP, IP, and TP, is negligible (

Ki​ > 100 µM), indicating its selectivity for the EP receptor family.[12] This profile, with strong agonism at multiple EP subtypes, allows it to act as a "master key," unlocking different physiological responses depending on the tissue's specific receptor landscape.

Gastroprotective Mechanism (The Intended Action)

The original and FDA-approved indication for misoprostol is based on its ability to protect the gastric mucosa from injury, particularly that induced by NSAIDs. This protection is achieved through a dual mechanism involving both antisecretory and cytoprotective actions.

• Antisecretory Effect: Misoprostol directly mimics the action of endogenous prostaglandins on the stomach's parietal cells. By acting as an agonist at EP3 receptors on these cells, it inhibits the proton pump (H+/K+-ATPase), thereby suppressing the secretion of gastric acid.[1] This inhibition is dose-dependent and effective against basal (fasting), nocturnal, and stimulated acid production, including that triggered by food, histamine, and caffeine.[1]
• Cytoprotective Effect: Independent of acid suppression, misoprostol enhances the natural defensive barriers of the gastric and duodenal mucosa. It stimulates the secretion of viscous, alkaline mucus and bicarbonate from epithelial cells, which form a protective layer that neutralizes acid at the cell surface.[1] Furthermore, it promotes mucosal blood flow and causes edema in the mucosa and submucosa, leading to a thickening of the mucosal bilayer.[1] This reduces the back-diffusion of damaging hydrogen ions and preserves the tissue's capacity for regeneration and repair.[1]

This dual mechanism provides a near-perfect countermeasure to the specific pathology of NSAID-induced gastropathy. NSAIDs cause ulcers primarily by inhibiting cyclooxygenase (COX) enzymes, which blocks the synthesis of the very prostaglandins that maintain mucosal integrity.[24] Misoprostol acts as a direct replacement for these depleted prostaglandins, restoring both the antisecretory and cytoprotective functions that NSAIDs disrupt.[25] This mechanistic synergy explains why misoprostol is particularly effective for preventing NSAID-induced ulcers and can be superior to agents that only suppress acid, such as H2-receptor antagonists.[26]

Uterotonic and Cervical Ripening Mechanism (The "Off-Label" Action)

The same receptor-binding activity that protects the stomach produces profound effects in the uterus, forming the basis for misoprostol's extensive use in obstetrics and gynecology. These effects are mediated by prostaglandin receptors expressed on uterine and cervical tissues.

• Uterine Contractions: Misoprostol binds to EP1 and EP3 receptors on the smooth muscle cells of the myometrium (the muscular wall of the uterus).[1] This agonist activity triggers a signaling cascade that increases intracellular calcium concentrations, leading to smooth muscle contraction.[5] The result is a dose-dependent increase in the frequency, tone, and strength of uterine contractions.[1] This powerful uterotonic action is harnessed to induce labor, manage postpartum hemorrhage by compressing uterine blood vessels, and expel the products of conception during a medical abortion or miscarriage management.
• Cervical Ripening: The process of cervical softening and dilation, known as "ripening," is a prerequisite for labor and certain gynecological procedures. Misoprostol facilitates this process through a distinct but related mechanism. It is believed to promote the degradation of collagen within the dense connective tissue stroma of the cervix and reduce overall cervical tone.[1] This enzymatic breakdown of the structural matrix effectively remodels the cervix, making it softer, more pliable, and easier to dilate.

The combination of potent uterine stimulation and effective cervical ripening makes misoprostol a uniquely powerful agent for a wide range of obstetric and gynecological applications.

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The clinical versatility of misoprostol is profoundly influenced by its pharmacokinetic properties, particularly the way its absorption, onset, and duration of action can be manipulated by the route of administration. Clinicians have learned to exploit these route-dependent differences to tailor the drug's effect to specific therapeutic needs, turning a deep understanding of its ADME profile into a powerful clinical tool.

Absorption and Route-Dependent Bioavailability

Misoprostol is a prodrug that is rapidly converted to its active metabolite, misoprostol acid.[1] The pharmacokinetic profile of this active metabolite varies dramatically depending on how the drug is administered.

• Oral Administration: When taken orally, misoprostol is absorbed very rapidly, with the active metabolite reaching peak plasma concentration (Tmax) in approximately 8 to 12 minutes.[3] This route leads to a sharp, high peak concentration (Cmax) but is subject to extensive first-pass metabolism in the liver, resulting in a relatively short duration of action of about 2 to 3 hours.[1]
• Sublingual Administration: Placing the tablet under the tongue allows for direct absorption into the systemic circulation, bypassing the gastrointestinal tract and first-pass metabolism in the liver. This results in an even faster onset of action (Tmax ~11 minutes), a higher Cmax, and greater overall bioavailability compared to the oral route.[3] The duration of action is approximately 3 hours.[3]
• Vaginal Administration: When administered vaginally, absorption is significantly slower and more sustained. The onset of action is delayed (Tmax ~20 minutes or longer), and the peak plasma concentration is lower than with oral or sublingual routes.[3] However, this route avoids first-pass metabolism, leading to a longer duration of action (approximately 4 hours) and greater overall systemic exposure (area under the curve, or AUC).[3] This profile of slower onset and sustained action is often desirable for applications like labor induction.
• Buccal and Rectal Administration: The buccal (between the cheek and gum) and rectal routes exhibit pharmacokinetic profiles similar to the vaginal route, characterized by slower absorption, lower peak concentrations, and sustained plasma levels compared to oral administration.[7]

This strategic selection of administration route is a prime example of applied pharmacology. For an emergency like postpartum hemorrhage, where rapid, powerful uterine contraction is needed, the sublingual or rectal routes are preferred for their fast onset and high peak concentrations.[21] Conversely, for labor induction, where a gradual and sustained effect is required to ripen the cervix and initiate contractions, the vaginal route is often chosen for its prolonged duration of action.[29]

Influence of Food and Antacids

The absorption of orally administered misoprostol is affected by the presence of food and certain medications.

• Food: Co-administration with food, particularly a high-fat meal, significantly slows the rate of absorption, increasing Tmax from approximately 14 minutes to 64 minutes.[18] It also reduces the peak plasma concentration (Cmax) by more than half. While the total amount of drug absorbed (AUC) is not significantly altered, this blunting of the peak concentration is clinically important. The common side effect of diarrhea is linked to high Cmax values; therefore, taking misoprostol with food is a key strategy to improve its tolerability and minimize gastrointestinal distress.[20]
• Antacids: Concomitant use of antacids can reduce the bioavailability of misoprostol acid. This effect is particularly pronounced with magnesium-containing antacids, which not only decrease absorption but can also exacerbate the drug's diarrheal side effects.[3]

Distribution

Once absorbed and converted to misoprostol acid, the drug distributes throughout the body. The parent compound, misoprostol, is less than 90% bound to serum proteins.[3] Its active metabolite, misoprostol acid, is also highly protein-bound, at a rate of 81-89%.[3] Misoprostol is known to be excreted into breast milk. Levels of misoprostol acid in breast milk peak quickly (within 1 hour of maternal ingestion) and then decline rapidly, becoming virtually undetectable within 5 hours.[1]

Metabolism

Misoprostol is a classic example of a prodrug.[1] It is administered in an inactive form and must be metabolically activated in the body to exert its therapeutic effect. The activation step is a rapid and extensive de-esterification process that cleaves the methyl ester group, converting misoprostol into its biologically active free acid metabolite,

misoprostol acid (also known by the research code SC-30695).[1] This conversion is so efficient that the parent compound is often undetectable in plasma following administration.[3] Misoprostol acid is then further metabolized into inactive dinor and tetranor metabolites before excretion.[3]

Excretion

The elimination of misoprostol from the body is relatively rapid. The terminal half-life of its active metabolite, misoprostol acid, is short, estimated to be between 20 and 40 minutes.[18] Following metabolism, the inactive metabolites are primarily cleared from the body via the kidneys, with approximately 80% of the drug being excreted in the urine.[1]

The table below provides a comparative summary of misoprostol's key pharmacokinetic parameters across different administration routes, illustrating the basis for its tailored clinical use.

Table 2: Comparative Pharmacokinetics of Misoprostol by Administration Route

Parameter	Oral	Sublingual	Vaginal	Rectal
Onset of Action	~8 minutes 3	~11 minutes 3	~20 minutes 3	Slower than oral/sublingual 7
Time to Peak (Tmax)	~12 minutes 18	Faster than oral 7	Slower than oral 6	Similar to vaginal 7
Peak Concentration (Cmax)	High, sharp peak 18	Highest peak 7	Lower, broader peak 6	Lower peak than sublingual 7
Duration of Action	~2-3 hours 1	~3 hours 3	~4 hours 3	Sustained action 7
Bioavailability (AUC)	Lower (first-pass effect) 7	Highest 7	High (no first-pass effect) 28	High (no first-pass effect) 7
Primary Clinical Rationale	Gastric protection; ease of use	Emergency uterotonic (e.g., PPH)	Sustained effect (e.g., labor induction)	Alternative for PPH when oral/sublingual not feasible

Clinical Applications and Efficacy

Misoprostol's clinical utility is a tale of two distinct, yet equally significant, identities. Its journey began with a single, narrow FDA-approved indication for gastrointestinal protection. However, its profound off-label effects on the uterus, discovered through grassroots use and later validated by extensive research, have transformed it into an indispensable tool in obstetrics and gynecology worldwide. This evolution represents a remarkable case study of how real-world clinical need can redefine a drug's primary purpose, eventually compelling acknowledgment from regulatory bodies and professional organizations.

FDA-Approved Indication

The sole indication for which misoprostol (as Cytotec) is officially approved by the U.S. Food and Drug Administration is for reducing the risk of gastric ulcers induced by nonsteroidal anti-inflammatory drugs (NSAIDs).[1]

• Prevention of NSAID-Induced Gastric Ulcers: Misoprostol is indicated specifically for patients at high risk of developing complications from gastric ulcers, such as the elderly or patients with concomitant debilitating diseases or a history of ulceration.[3] It is intended to be taken for the duration of NSAID therapy. The standard dosage regimen is 200 mcg administered orally four times a day, with meals and at bedtime to improve tolerability.[20] Clinical trials have demonstrated its efficacy, with one meta-analysis showing a 74% decrease in endoscopic gastric ulcers compared to placebo.[26] The FDA approval specifies its efficacy for gastric ulcers but not duodenal ulcers in this context.[3] Misoprostol is also available as a fixed-dose combination tablet with the NSAID diclofenac (brand name Arthrotec), designed to provide pain relief for patients with osteoarthritis or rheumatoid arthritis while simultaneously protecting the gastric mucosa.[3]

Off-Label Uses in Obstetrics and Gynecology (The "Second Life")

Despite its narrow approved indication, the vast majority of misoprostol's use today is in obstetrics and gynecology. These off-label applications are supported by a massive body of scientific evidence and are recommended by leading professional organizations like the American College of Obstetricians and Gynecologists (ACOG).[4]

• Medical Termination of Pregnancy: Misoprostol is a cornerstone of modern medical abortion. While its use as a single agent for this purpose is off-label, it is a critical component of an FDA-approved combination regimen. The approved protocol involves an oral dose of mifepristone (an antiprogestin) followed 24-48 hours later by 800 mcg of misoprostol, typically administered via the buccal or vaginal route.[1] This combination is highly effective (over 95%) for terminating intrauterine pregnancies up to 70 days of gestation and has become the dominant method for first-trimester abortions in many countries.[5]
• Management of Miscarriage (Early Pregnancy Loss): For patients experiencing an incomplete or missed abortion, misoprostol offers a non-surgical alternative to dilation and curettage (D&C). A single dose of 600 mcg orally or 800 mcg vaginally can induce uterine contractions to expel the retained products of conception, effectively managing the miscarriage medically.[3]
• Cervical Ripening and Labor Induction: Low doses of misoprostol are widely used to prepare the cervix for labor and to induce labor in women with term pregnancies. A common regimen involves inserting 25 mcg vaginally every 3 to 6 hours.[29] Its ability to both soften the cervix and stimulate contractions makes it highly effective.[1] While the FDA has issued alerts regarding the risks of this off-label use, particularly uterine rupture, its efficacy and low cost have led to its establishment as a standard of care in many institutions when used appropriately in carefully selected patients.[41]
• Prevention and Treatment of Postpartum Hemorrhage (PPH): PPH is a leading cause of maternal mortality globally. Misoprostol serves as a critical second-line agent for treating PPH due to uterine atony, especially when injectable uterotonics like oxytocin are unavailable or ineffective.[30] A single high dose of 600-1000 mcg (administered orally, sublingually, or rectally) can produce the powerful, sustained uterine contraction needed to control bleeding.[29] Its properties—affordability, heat stability, and ease of oral administration—make it a life-saving intervention in low-resource settings where the cold chain required for oxytocin may not be available. This application elevates misoprostol from a simple pharmaceutical to a critical tool for global health equity.[43]
• Cervical Dilation Prior to Uterine Procedures: Misoprostol is used off-label to soften and dilate the cervix before surgical procedures such as hysteroscopy, or to ease the insertion of an intrauterine device (IUD).[21] Clinical trials have investigated its efficacy for this purpose, comparing it to other methods like lidocaine spray.[46]

Investigational and Other Uses

Research continues to explore new applications for misoprostol's prostaglandin-mimicking effects.

• Erythromelalgia: A double-blind, placebo-controlled crossover study demonstrated that oral misoprostol (0.4-0.8 mg daily) was clinically superior to placebo in reducing the pain, heat, and redness associated with erythromelalgia, a rare and painful neurovascular disorder. The mechanism is hypothesized to be a reduction in microvascular arteriovenous shunting in the affected skin.[47]
• Cervical Cancer Screening: A clinical trial is currently recruiting participants to investigate the use of misoprostol to optimize the prevention of cervical cancer, suggesting a potential role in enhancing screening or diagnostic procedures.[48]

The following table summarizes the diverse clinical applications of misoprostol, highlighting the significant contrast between its official label and its extensive, evidence-based real-world use.

Table 3: Summary of Clinical Indications, Dosage Regimens, and Administration Routes for Misoprostol

Indication	Regulatory Status	Typical Dosage and Frequency	Route(s) of Administration
Prevention of NSAID-Induced Gastric Ulcers	FDA-Approved	200 mcg four times daily	Oral
Medical Termination of Pregnancy	FDA-Approved (in combination with mifepristone)	800 mcg single dose (24-48h after mifepristone)	Buccal, Vaginal
Management of Miscarriage (Early Pregnancy Loss)	Off-Label (ACOG Recommended)	600-800 mcg single dose; may be repeated	Oral, Vaginal, Sublingual
Cervical Ripening & Labor Induction	Off-Label (ACOG Recommended)	25-50 mcg every 3-6 hours	Vaginal, Oral
Treatment of Postpartum Hemorrhage (PPH)	Off-Label (WHO/FIGO Recommended)	800-1000 mcg single dose	Rectal, Sublingual, Oral
Prevention of Postpartum Hemorrhage (PPH)	Off-Label (WHO/FIGO Recommended)	600 mcg single dose immediately after delivery	Oral
Cervical Dilation (pre-IUD/hysteroscopy)	Off-Label	400 mcg single dose 1-3 hours prior	Sublingual, Vaginal

Safety Profile, Toxicology, and Risk Management

The safety profile of misoprostol is complex and defined by a central paradox: the very pharmacological action that makes it a powerful therapeutic tool in obstetrics is also the source of its most severe risks and its most stringent regulatory warning. A thorough understanding of its adverse effects, contraindications, and the FDA's Black Box Warning is essential for its safe clinical use.

FDA Black Box Warning

The U.S. Food and Drug Administration has assigned a Black Box Warning to misoprostol (Cytotec), its most serious level of warning, to emphasize the life-threatening risks associated with its use in the wrong clinical context.[8] The warning is multifaceted and addresses several critical points:

• Risk in Pregnancy (for Ulcer Indication): The primary warning explicitly states that administering misoprostol to pregnant women for its approved indication (prevention of NSAID-induced ulcers) is contraindicated. Its potent uterotonic effects can cause abortion, premature birth, or significant birth defects.[8]
• Risk of Uterine Rupture: The warning highlights the risk of uterine rupture, a catastrophic and potentially fatal event for both mother and fetus. This risk is significantly increased when misoprostol is used off-label to induce labor or abortion, particularly in later gestational stages and, most critically, in women with a history of prior uterine surgery, including a Cesarean delivery.[8] The risk is not binary but exists on a spectrum, escalating with higher doses and in patients with a scarred uterus.[8] This nuanced understanding is crucial for risk stratification in clinical practice.
• Mandatory Patient Counseling and Risk Mitigation: To prevent inadvertent exposure during pregnancy, the FDA mandates strict precautions for prescribing misoprostol to women of childbearing potential for the ulcer indication. These include:

1. A negative serum pregnancy test within two weeks prior to starting therapy.[8]
2. Initiation of therapy only on the second or third day of the next normal menstrual period.[8]
3. Commitment from the patient to use effective contraception throughout treatment.[8]
4. Providing both oral and written warnings about the drug's abortifacient properties and the danger of sharing the medication.[8]

Adverse Effects

The adverse effects of misoprostol are largely predictable extensions of its prostaglandin-mediated mechanisms.

• Gastrointestinal Effects: These are the most commonly reported side effects, particularly when the drug is taken orally for the ulcer indication.
• Diarrhea: This is the most frequent adverse event, occurring in 13-40% of patients. It is dose-related, typically appears early in therapy, and is usually self-limiting. However, in rare cases, it can be profound and lead to severe dehydration.[32]
• Abdominal Pain: Occurs in 7-20% of patients.[32]
• Other GI Effects: Nausea, vomiting, flatulence, dyspepsia, and constipation are also reported.[1] The incidence of diarrhea can be minimized by taking the drug with food and avoiding magnesium-containing antacids.[32]
• Gynecological and Obstetric Effects: When used for obstetric purposes, the intended therapeutic effects can also manifest as adverse events.
• Uterine Cramping and Bleeding: These are expected effects during medical abortion or miscarriage management but can be severe.[49] Other reported effects include spotting, hypermenorrhea (heavy menstrual bleeding), and menstrual irregularities.[32]
• Uterine Hyperstimulation (Tachysystole): Overly frequent or strong uterine contractions can occur, especially with higher doses used for labor induction, potentially leading to fetal heart rate decelerations and fetal distress.[25]
• Systemic Effects: Particularly with the higher doses used in obstetrics, systemic side effects are common. These include shivering, chills, hyperthermia (fever), and headache.[52]
• Serious and Rare Events: With off-label obstetric use, serious complications have been reported, including anaphylactic reactions, maternal shock, amniotic fluid embolism (a rare but often fatal complication of childbirth), and fetal bradycardia or death.[30]

Contraindications and Precautions

• Absolute Contraindications:

1. Pregnancy (for the ulcer indication): This is the central contraindication highlighted in the Black Box Warning.[24]
2. Known Allergy/Hypersensitivity: Patients with a known allergy to misoprostol or other prostaglandins should not receive the drug.[1]

• Precautions:
• Cardiovascular Disease: Caution is advised in patients with pre-existing cardiovascular disease, as drug-induced hypotension could precipitate severe complications like myocardial infarction or stroke.[22]
• Inflammatory Bowel Disease (IBD): Due to the high incidence of diarrhea, misoprostol should be used with caution in patients with IBD (e.g., Crohn's disease, ulcerative colitis), as it could exacerbate their condition.[57]

Teratogenicity (Risk of Birth Defects)

In cases where misoprostol administration in early pregnancy fails to cause an abortion, the fetus is exposed to a risk of congenital malformations. This teratogenic effect is not random but is associated with a specific pattern of defects thought to be caused by vascular disruption secondary to the intense uterine contractions induced by the drug.[33] This can compromise blood flow to the developing fetus, leading to tissue hypoxia and developmental abnormalities. The constellation of birth defects associated with prenatal misoprostol exposure includes:

• Moebius Syndrome: A rare neurological condition characterized by weakness or paralysis of multiple cranial nerves, most often the facial and abducens nerves, leading to a "mask-like" facial expression and impaired eye movement.[33]
• Limb Defects: Terminal transverse limb defects, such as missing fingers, toes, or parts of arms and legs.[33]
• Other Malformations: Skull defects, arthrogryposis (multiple joint contractures), and craniofacial anomalies like cleft lip and/or palate have also been reported.[33]

The absolute risk of these malformations following first-trimester exposure is estimated to be relatively low, around 1%, but the severity of the potential defects underscores the importance of the warnings against its use during pregnancy.[33]

Overdose

Overdose of misoprostol is rare, but symptoms are extensions of its known pharmacological effects. Patients may present with sedation, tremor, convulsions, dyspnea (difficulty breathing), abdominal pain, diarrhea, fever, palpitations, hypotension (low blood pressure), and bradycardia (slow heart rate).[3] Treatment is supportive and symptomatic. Due to high protein binding, hemodialysis is not expected to be an effective method for clearing the drug, but oral activated charcoal may be administered to reduce further absorption from the GI tract.[3]

Drug and Food Interactions

The interactions of misoprostol with other drugs and with food are primarily pharmacodynamic in nature, meaning they result from additive or opposing effects at the site of action, rather than significant alterations in metabolism. Understanding these interactions is crucial for maximizing efficacy and minimizing adverse events. The lack of significant pharmacokinetic interactions with many common drugs is also a key safety feature.

Drug-Drug Interactions

The most clinically relevant interactions involve agents that share similar therapeutic effects or side effects with misoprostol.

• Magnesium-Containing Antacids: This is a major and well-documented interaction. Misoprostol's most common side effect is diarrhea. Magnesium salts are also known to have a laxative effect. When used concurrently, magnesium-containing antacids can significantly potentiate misoprostol-induced diarrhea.[3] For patients taking misoprostol who require an antacid, it is strongly recommended to use products containing aluminum or calcium hydroxide instead.[30]
• Oxytocic Agents: Misoprostol and other uterotonic drugs, such as oxytocin, have synergistic effects on the uterus. Both agents stimulate uterine contractions. When used together, especially in close succession, their combined effect can lead to uterine hyperstimulation (tachysystole), which can compromise fetal oxygen supply.[30] To mitigate this risk, it is recommended to wait at least 4 hours after the last dose of misoprostol before initiating an oxytocin infusion for labor augmentation or induction.[30]
• Other Drugs Causing Diarrhea: Although less emphasized than the magnesium interaction, caution is advised when co-administering misoprostol with other medications known to cause diarrhea, such as crofelemer or eluxadoline, due to the potential for additive gastrointestinal side effects.[61]
• Lack of Significant Pharmacokinetic Interactions: An important aspect of misoprostol's interaction profile is its lack of interference with the metabolism of many other drugs. Clinical studies have shown that misoprostol does not significantly affect the pharmacokinetics of commonly co-prescribed NSAIDs like ibuprofen and diclofenac.[24] This is a critical safety feature for its primary approved indication, as it ensures that neither the NSAID's anti-inflammatory effect nor misoprostol's protective effect is compromised. Similarly, no clinically significant interactions have been found with diazepam, propranolol, or antipyrine.[24]

Drug-Food Interactions

• Food (General): As detailed in the Pharmacokinetics section, the co-administration of misoprostol with food, especially high-fat meals, has a significant impact on its absorption profile. Food slows the rate of absorption and lowers the peak plasma concentration (Cmax) of the active metabolite, misoprostol acid.[18] This pharmacokinetic interaction is leveraged clinically as a primary strategy to manage the drug's main side effect. By blunting the Cmax, taking misoprostol with meals reduces the incidence and severity of diarrhea and stomach cramps, making the therapeutic dose more tolerable.[20]
• Alcohol: While there is no specific pharmacokinetic interaction between misoprostol and alcohol, their concurrent use is discouraged. Alcohol is a gastric irritant and can exacerbate the risk of stomach damage, potentially counteracting the protective effects of misoprostol.[58] In the context of obstetric use, consuming alcohol is contraindicated as it can impair a patient's judgment during a critical medical process where they need to monitor for bleeding and other complications.[63]
• Grapefruit Juice: There is no known interaction between misoprostol and grapefruit juice. This interaction is relevant for mifepristone, the drug with which misoprostol is frequently combined for medical abortion, as grapefruit juice can inhibit the CYP3A4 enzyme responsible for mifepristone's metabolism.[64] This distinction is important to avoid confusion when the two drugs are used in a combination regimen.

The following table summarizes the most clinically important interactions for misoprostol and provides clear management recommendations.

Table 4: Clinically Significant Drug Interactions and Management Recommendations for Misoprostol

Interacting Agent(s)	Mechanism of Interaction	Clinical Consequence	Management Strategy
Magnesium-Containing Antacids (e.g., Magnesium Hydroxide)	Additive Pharmacodynamic Effect	Potentiation of diarrhea, potentially leading to dehydration.	Avoid combination. If an antacid is required, select a non-magnesium-containing product (e.g., aluminum or calcium-based).
Oxytocic Agents (e.g., Oxytocin)	Synergistic Pharmacodynamic Effect	Increased risk of uterine hyperstimulation (tachysystole), which can lead to fetal distress.	Avoid concurrent use. If oxytocin is needed after misoprostol, a time interval of at least 4 hours between the last misoprostol dose and the start of oxytocin is recommended. Monitor uterine activity and fetal status closely.
Food (especially high-fat meals)	Pharmacokinetic Interaction (slows absorption, lowers Cmax)	Reduction in the incidence and severity of diarrhea and abdominal cramping.	Administer with food. This is a recommended strategy to improve the tolerability of oral misoprostol, especially for the gastroprotective indication.
Alcohol	Pharmacodynamic Interaction (gastric irritation); Impaired Judgment	Increased gastric irritation, potentially counteracting the therapeutic effect. Impaired ability to recognize and respond to complications during obstetric use.	Avoid alcohol. Advise patients to refrain from alcohol consumption while taking misoprostol.

Synthesis and Concluding Remarks

Misoprostol stands as one of the most remarkable and complex drugs in the modern pharmacopeia. Its trajectory from a modestly successful agent for preventing stomach ulcers to an indispensable, life-saving medicine in global reproductive health encapsulates a powerful narrative about drug development, clinical innovation, and the societal impact of pharmacology. This monograph has detailed its chemical foundations, dual mechanisms of action, versatile pharmacokinetics, and its wide-ranging clinical applications, all of which are shadowed by a significant and paradoxical safety profile.

The story of misoprostol is fundamentally a story of dual identity. It was designed and approved for one purpose—to protect the gastric mucosa by mimicking endogenous prostaglandins.[66] Yet, its most profound impact has come from its "second life," an identity forged not in corporate laboratories but through the real-world experiences of women and clinicians who discovered its potent uterotonic properties.[67] This has positioned misoprostol as a quintessential case study in off-label drug use. Its journey from grassroots application to inclusion in the guidelines of major international health organizations like the WHO and ACOG demonstrates a powerful, bottom-up paradigm of medical innovation, where overwhelming evidence and undeniable clinical need eventually reshape formal medical practice and regulatory perspectives.[4]

Furthermore, the physicochemical properties of misoprostol—its low cost, oral bioavailability, and stability at room temperature—have elevated it beyond a mere therapeutic option to a cornerstone of global health equity.[43] In low-resource settings, where the infrastructure required for injectable uterotonics like oxytocin is often lacking, misoprostol provides a "low-tech, high-impact" solution to postpartum hemorrhage, one of the leading causes of maternal mortality worldwide. Its role in making medical abortion safer and more accessible has had a similarly transformative effect on reproductive health globally.

This immense benefit, however, is inextricably linked to an enduring tension with its risks. The drug's central paradox is that its primary therapeutic mechanism in obstetrics—the powerful induction of uterine contractions—is the very source of its Black Box Warning and its potential for catastrophic harm when used in the wrong context.[8] The risk of uterine rupture, particularly in women with prior Cesarean sections, and its known teratogenicity demand a profound respect for the drug's power.[33]

In conclusion, the safe and effective use of misoprostol is not simple. It requires a nuanced understanding that transcends its official label. It demands that clinicians master its route-dependent pharmacokinetics to tailor therapy, conduct meticulous patient selection to mitigate risks, and provide comprehensive counseling to ensure patient understanding. Misoprostol is more than a chemical compound; it is a reflection of medicine's evolution, a tool of global health, and a testament to the fact that a drug's ultimate value is defined not only by its intended design but by its proven impact in the hands of those who use it to save lives.

Works cited

1. Misoprostol - StatPearls - NCBI Bookshelf, accessed July 15, 2025, https://www.ncbi.nlm.nih.gov/books/NBK539873/
2. www.ncbi.nlm.nih.gov, accessed July 15, 2025, https://www.ncbi.nlm.nih.gov/books/NBK539873/#:~:text=Misoprostol%20is%20a%20synthetic%20prostaglandin,%2Dinflammatory%20drugs%20(NSAIDs).
3. Misoprostol: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 15, 2025, https://go.drugbank.com/drugs/DB00929
4. Off-Label Use - Misoprostol.org, accessed July 15, 2025, http://www.misoprostol.org/off-label-use/
5. What is the mechanism of Misoprostol? - Patsnap Synapse, accessed July 15, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-misoprostol
6. Misoprostol: Theory and Practice - The Global Library of Women's Medicine, accessed July 15, 2025, https://www.glowm.com/pdf/PPH_2nd_edn_Chap-32.pdf
7. Misoprostol: Pharmacokinetic profiles, effects on the uterus and side-effects, accessed July 15, 2025, https://misoprostol.org/downloads/misoprostol-journals/IJGO_pharm_Tang.pdf
8. CYTOTEC® (misoprostol) Boxed Warning | Pfizer Medical - US, accessed July 15, 2025, https://www.pfizermedical.com/cytotec/boxed-warning
9. Misoprostol | C22H38O5 - ChemSpider, accessed July 15, 2025, https://www.chemspider.com/Chemical-Structure.4445541.html
10. Misoprostol | C22H38O5 | CID 5282381 - PubChem, accessed July 15, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Misoprostol
11. Misoprostol, Cytoprotective PGE2 analog (CAS 59122-46-2) (ab120902) | Abcam, accessed July 15, 2025, https://www.abcam.com/en-us/products/biochemicals/misoprostol-cytoprotective-pge2-analog-ab120902
12. Misoprostol (SC 29333, CAS Number: 59122-46-2) | Cayman Chemical, accessed July 15, 2025, https://www.caymanchem.com/product/13820/misoprostol
13. Misoprostol | 59122-46-2 - ChemicalBook, accessed July 15, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7713293.htm
14. CAS No : 59122-46-2| Product Name : Misoprostol - API - Pharmaffiliates, accessed July 15, 2025, https://www.pharmaffiliates.com/en/59122-46-2-misoprostol-api-pa4009000.html
15. [Misoprostol (100 mg)] - CAS [59122-46-2] - USP Store, accessed July 15, 2025, https://store.usp.org/product/1444300
16. MISOPROSTOL - USAID Global Health Supply Chain Program, accessed July 15, 2025, https://www.ghsupplychain.org/sites/default/files/2019-02/MNCH%20Commodities-Misoprostol.pdf
17. (11R,16S)-misoprostol | C22H38O5 | CID 9886273 - PubChem, accessed July 15, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/9886273
18. Cytotec® - accessdata.fda.gov, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/19268slr037.pdf
19. Misoprostol | CAS 59122-46-2 | SCBT - Santa Cruz Biotechnology, accessed July 15, 2025, https://www.scbt.com/p/misoprostol-59122-46-2
20. Misoprostol (oral route) - Mayo Clinic, accessed July 15, 2025, https://www.mayoclinic.org/drugs-supplements/misoprostol-oral-route/description/drg-20064805
21. MISOPROSTOL oral - MSF Medical Guidelines, accessed July 15, 2025, https://medicalguidelines.msf.org/en/viewport/EssDr/english/misoprostol-oral-16684219.html
22. SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM: CYTOTEC® Tablets COMPOSITION - Pfizer, accessed July 15, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=1064
23. Showing BioInteractions for Misoprostol (DB00929) | DrugBank Online, accessed July 15, 2025, https://go.drugbank.com/drugs/DB00929/biointeractions
24. Cytotec® misoprostol tablets WARNINGS CYTOTEC (MISOPROSTOL) ADMINISTRATION TO WOMEN WHO ARE PREGNANT CAN CAUSE BIRTH DEFECTS, A - accessdata.fda.gov, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019268s047lbl.pdf
25. Misoprostol: Uses, Dosage, Side Effects & Warnings - Drugs.com, accessed July 15, 2025, https://www.drugs.com/misoprostol.html
26. What is the use of misoprostol (prostaglandin E1 analogue)? - Dr.Oracle AI, accessed July 15, 2025, https://www.droracle.ai/articles/102669/what-is-misoprostol-used-for
27. A Relative Bioavailability Study of Two Misoprostol Formulations Following a Single Oral or Sublingual Administration - Frontiers, accessed July 15, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.00050/full
28. Misoprostol use in obstetrics: Number 6 - June 2023 - SciELO, accessed July 15, 2025, https://www.scielo.br/j/rbgo/a/PZVWyH4jgNSrFxGmSXrnr9v/
29. Misoprostol Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed July 15, 2025, https://www.drugs.com/dosage/misoprostol.html
30. Cytotec (misoprostol) dosing, indications, interactions, adverse effects, and more, accessed July 15, 2025, https://reference.medscape.com/drug/cytotec-misoprostol-341995
31. Effects of food and antacid on oral absorption of misoprostol, a synthetic prostaglandin E1 analog - PubMed, accessed July 15, 2025, https://pubmed.ncbi.nlm.nih.gov/2500461/
32. Cytotec (Misoprostol): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed July 15, 2025, https://www.rxlist.com/cytotec-drug.htm
33. Uses of Misoprostol in Obstetrics and Gynecology - PMC, accessed July 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2760893/
34. Cytotec® misoprostol tablets WARNINGS CYTOTEC (MISOPROSTOL) ADMINISTRATION TO WOMEN WHO ARE PREGNANT CAN CAUSE ABORTION, PREMAT - accessdata.fda.gov, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019268s041lbl.pdf
35. Misoprostol oral tablet: Dosage, side effects, uses, and more - Medical News Today, accessed July 15, 2025, https://www.medicalnewstoday.com/articles/drugs-misoprostol-tablet
36. FDA gives nod to label change for misoprostol - Relias Media, accessed July 15, 2025, https://www.reliasmedia.com/articles/79534-fda-gives-nod-to-label-change-for-misoprostol
37. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MIFEPRISTONE TABLETS, 20 - FDA, accessed July 15, 2025, https://www.fda.gov/media/164653/download
38. highlights of prescribing information - accessdata.fda.gov, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020687s022lbl.pdf
39. Abortion induced Completed Phase 2 Trials for Misoprostol (DB00929) | DrugBank Online, accessed July 15, 2025, https://go.drugbank.com/indications/DBCOND0025862/clinical_trials/DB00929?phase=2&status=completed
40. The History of Abortion Pills and How to Protect Future Access | Scholars Strategy Network, accessed July 15, 2025, https://scholars.org/contribution/history-abortion-pills-and-how-protect-future
41. Misoprostol (marketed as Cytotec) Information - FDA, accessed July 15, 2025, https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/misoprostol-marketed-cytotec-information
42. Cytotec (Misoprostol Labor Induction) and Birth Injuries, accessed July 15, 2025, https://birthinjurycenter.org/delivery-complications/cytotec-induction/
43. Prostaglandins for Postpartum Hemorrhage: Pharmacology, Application, and Current Opinion - Karger Publishers, accessed July 15, 2025, https://karger.com/pha/article/106/9-10/477/820467/Prostaglandins-for-Postpartum-Hemorrhage
44. Development of Misoprostol Suppositories for Postpartum Hemorrhage, accessed July 15, 2025, https://www.scirp.org/journal/paperinformation?paperid=27501
45. A Stalled Revolution? Misoprostol and the Pharmaceuticalization of Reproductive Health in Francophone Africa - Frontiers, accessed July 15, 2025, https://www.frontiersin.org/journals/sociology/articles/10.3389/fsoc.2021.590556/full
46. Prevention of Pregnancy Completed Phase 3 Trials for Misoprostol (DB00929) - DrugBank, accessed July 15, 2025, https://go.drugbank.com/indications/DBCOND0043943/clinical_trials/DB00929?phase=3&status=completed
47. The prostaglandin E1 analog misoprostol reduces symptoms and microvascular shunting in erythromelalgia, accessed July 15, 2025, https://burningfeet.org/wp-content/uploads/2017/10/11.-The-prostaglandin-E1-analog-misoprostol-reduces-symptoms.pdf
48. Cervical Cancer Recruiting Phase Trials for Misoprostol (DB00929) | DrugBank Online, accessed July 15, 2025, https://go.drugbank.com/indications/DBCOND0028450/clinical_trials/DB00929?phase=&status=recruiting
49. Misoprostol oral tablet side effects: How to manage them - Medical News Today, accessed July 15, 2025, https://www.medicalnewstoday.com/articles/drugs-misoprostol-tablet-side-effects
50. Misoprostol: MedlinePlus Drug Information, accessed July 15, 2025, https://medlineplus.gov/druginfo/meds/a689009.html
51. CYTOTEC® (misoprostol) Boxed Warning Patient information | Pfizer Medical Information - US, accessed July 15, 2025, https://www.pfizermedicalinformation.com/patient/cytotec/boxed-warning
52. www.ncbi.nlm.nih.gov, accessed July 15, 2025, https://www.ncbi.nlm.nih.gov/books/NBK539873/#:~:text=The%20most%20commonly%20reported%20adverse,breakthrough%20bleeding%2C%20and%20menstrual%20irregularities.
53. Misoprostol - Memorial Sloan Kettering Cancer Center, accessed July 15, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/adult/misoprostol
54. (diclofenac sodium/misoprostol) Tablets CONTRAINDICATIONS AND WARNINGS ARTHROTEC - accessdata.fda.gov, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020607s021lbl.pdf
55. www.ncbi.nlm.nih.gov, accessed July 15, 2025, https://www.ncbi.nlm.nih.gov/books/NBK539873/#:~:text=Misoprostol%20is%20contraindicated%20in%20individuals,serious%20adverse%20effects%20during%20pregnancy.
56. CYTOTEC® (misoprostol) Contraindications Patient information | Pfizer Medical Information - US, accessed July 15, 2025, https://www.pfizermedicalinformation.com/patient/cytotec/contradictions
57. Misoprostol Disease Interactions - Drugs.com, accessed July 15, 2025, https://www.drugs.com/disease-interactions/misoprostol.html?professional=1
58. Misoprostol (Cytotec): Uses & Side Effects - Cleveland Clinic, accessed July 15, 2025, https://my.clevelandclinic.org/health/drugs/18350-misoprostol-tablets
59. Misoprostol (Cytotec®) - MotherToBaby, accessed July 15, 2025, https://mothertobaby.org/fact-sheets/misoprostol-cytotec/
60. CYTOTEC® (misoprostol) Warnings and Precautions | Pfizer Medical - US, accessed July 15, 2025, https://www.pfizermedical.com/cytotec/warnings
61. Misoprostol: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed July 15, 2025, https://www.rxlist.com/misoprostol/generic-drug.htm
62. Diclofenac/misoprostol and Alcohol/Food Interactions - Drugs.com, accessed July 15, 2025, https://www.drugs.com/food-interactions/diclofenac-misoprostol.html
63. Can you eat or drink after taking misoprostol? - Aid Access, accessed July 15, 2025, https://aidaccess.org/en/page/453/can-you-eat-or-drink-while-you-are-taking-the-medicines
64. Mifepristone (oral route) - Mayo Clinic, accessed July 15, 2025, https://www.mayoclinic.org/drugs-supplements/mifepristone-oral-route/description/drg-20067123
65. Mifepristone and Alcohol/Food Interactions - Drugs.com, accessed July 15, 2025, https://www.drugs.com/food-interactions/mifepristone.html
66. Misoprostol: discovery, development, and clinical applications - PubMed, accessed July 15, 2025, https://pubmed.ncbi.nlm.nih.gov/2109814/
67. The history of abortion | Hey Jane, accessed July 15, 2025, https://www.heyjane.com/articles/history-of-abortion
68. The chemical geographies of misoprostol: Spatializing abortion access from the biochemical to the global - PMC - PubMed Central, accessed July 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7615505/